Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials
作者： Guosheng Yin , Zhao Yang , Motoi Odani , Satoru Fukimbara
DOI: 10.1080/19466315.2020.1811146
关键词:
摘要: Patients’ heterogeneity poses a fundamental problem in the rapidly developing field of precision medicine. Based on prespecified cutoff, biomarker-based designs provide flexible approach to sel...
sci-hub.st 参考文章(38)
Sumithra J. Mandrekar, Daniel J. Sargent, Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine Chinese clinical oncology. ,vol. 3, pp. 14- 14 ,(2014) , 10.3978/J.ISSN.2304-3865.2014.05.03
Scott M Berry, Kristine R Broglio, Susan Groshen, Donald A Berry, Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials: Clinical Trials. ,vol. 10, pp. 720- 734 ,(2013) , 10.1177/1740774513497539
J Jack Lee, Diane D Liu, A predictive probability design for phase II cancer clinical trials Clinical Trials. ,vol. 5, pp. 93- 106 ,(2008) , 10.1177/1740774508089279
Lorenzo Trippa, Yanxun Xu, Peter Müller, Yuan Ji, Yuan Ji, Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. Statistics in Biosciences. ,vol. 8, pp. 159- 180 ,(2016) , 10.1007/S12561-014-9117-1
Amanda J. Redig, Pasi A. Jänne, Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine Journal of Clinical Oncology. ,vol. 33, pp. 975- 977 ,(2015) , 10.1200/JCO.2014.59.8433
Boris Freidlin, Wenyu Jiang, Richard Simon, The Cross-Validated Adaptive Signature Design Clinical Cancer Research. ,vol. 16, pp. 691- 698 ,(2010) , 10.1158/1078-0432.CCR-09-1357
N. Simon, R. Simon, Adaptive enrichment designs for clinical trials Biostatistics. ,vol. 14, pp. 613- 625 ,(2013) , 10.1093/BIOSTATISTICS/KXT010
Boris Freidlin, Richard Simon, Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients Clinical Cancer Research. ,vol. 11, pp. 7872- 7878 ,(2005) , 10.1158/1078-0432.CCR-05-0605
Lisa M. McShane, Sally Hunsberger, Alex A. Adjei, Effective Incorporation of Biomarkers into Phase II Trials Clinical Cancer Research. ,vol. 15, pp. 1898- 1905 ,(2009) , 10.1158/1078-0432.CCR-08-2033
W. Jiang, B. Freidlin, R. Simon, Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute. ,vol. 99, pp. 1036- 1043 ,(2007) , 10.1093/JNCI/DJM022